Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System

    NEXT STORY
    Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System
    PREV STORY
    Revolution Medicines Announces Proposed Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

    author_avatar
    NASDAQ Market News

    BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017

    NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical ...

    author_avatar
    NASDAQ Market News

    Loop Insights Signs Contract with Summit One Source to Deliver Fully Integrated COVID-19 Lab Testing and Tracing Solution to NCAA, Healthcare, Hospitality, and USA Government

    author_avatar
    NASDAQ Market News